Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Alto Neuroscience, Inc. before investing.

In this article, we go over a few key elements for understanding Alto Neuroscience, Inc.’s stock price such as:

• Alto Neuroscience, Inc.’s current stock price and volume
• Why Alto Neuroscience, Inc.’s stock price changed recently
• Upgrades and downgrades for ANRO from analysts
• ANRO’s stock price momentum as measured by its relative strength

About Alto Neuroscience, Inc. (ANRO)

Before we jump into Alto Neuroscience, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Want to learn more about Alto Neuroscience, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Alto Neuroscience, Inc..

Alto Neuroscience, Inc.’s Stock Price as of Market Close

As of December 22, 2025, 2:01 PM, CST, Alto Neuroscience, Inc.’s stock price was $20.090.

Alto Neuroscience, Inc. is up 0.55% from its previous closing price of $19.980.

During the last market session, Alto Neuroscience, Inc.’s stock traded between $19.300 and $20.210. Currently, there are approximately 27.10 million shares outstanding for Alto Neuroscience, Inc..

Alto Neuroscience, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Alto Neuroscience, Inc. Stock Price History

Alto Neuroscience, Inc.’s (ANRO) price is currently up 45.05% so far this month.

During the month of December, Alto Neuroscience, Inc.’s stock price has reached a high of $20.910 and a low of $12.510.

Over the last year, Alto Neuroscience, Inc. has hit prices as high as $20.908 and as low as $1.600. Year to date, Alto Neuroscience, Inc.’s stock is up 374.94%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Alto Neuroscience, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 19, 2025, there was 1 analyst who downgraded Alto Neuroscience, Inc.’s stock and 4 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Alto Neuroscience, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Alto Neuroscience, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Alto Neuroscience, Inc. (ANRO) by visiting AAII Stock Evaluator.

Relative Price Strength of Alto Neuroscience, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 19, 2025, Alto Neuroscience, Inc. has a weighted four-quarter relative price strength of 152.40%, which translates to a Momentum Score of 100 and is considered to be Very Strong.

Want to learn more about how Alto Neuroscience, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Alto Neuroscience, Inc. Stock Price: Bottom Line

As of December 22, 2025, Alto Neuroscience, Inc.’s stock price is $20.090, which is up 0.55% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Alto Neuroscience, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.